Pelthos Therapeutics Inc. (PTHS) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Pelthos Therapeutics Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Pelthos Therapeutics Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Pelthos Therapeutics Inc. actually do?
Answer:
Pelthos Therapeutics Inc. is a bio-pharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The company's portfolio includes three FDA-approved products: ZELSUVMI, XEPI, and XEGLYZE. ZELSUVMI, a topical gel for molluscum contagiosum, was launched in July 2025. In late 2025, Pelthos acquired XEPI for impetigo and XEGLYZE for head lice, with plans for future commercialization. The company also has clinical-stage assets targeting NaV1.7 for pain management. Pelthos operates with a manufacturing facility for its ZELSUVMI API and leverages the NITRICIL technology platform.
Question:
What are Pelthos Therapeutics Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by the sales of ZELSUVMI, with plans to commercialize XEPI and XEGLYZE. License and collaboration revenues also contribute to overall revenue.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required